



## First Case Report of Bacteremia Due to *Catabacter hongkongensis* in a Korean Patient

Yong Jun Choi, M.D.<sup>1,\*</sup>, Eun Jeong Won, M.D.<sup>1,\*</sup>, Soo Hyun Kim, M.D.<sup>1,2</sup>, Myung Geun Shin, M.D.<sup>1</sup>, Jong Hee Shin, M.D.<sup>1</sup>, and Soon Pal Suh, M.D.<sup>1</sup>

Department of Laboratory Medicine<sup>1</sup>, Research Institute of Medical Sciences<sup>2</sup>, Chonnam National University Medical School, Gwangju, Korea

Dear Editor,

*Catabacter hongkongensis*, a newly described anaerobic Gram-positive coccobacillus pathogen, was first isolated in 2007; its draft genome sequence was revealed in 2015 [1, 2]. *C. hongkongensis* infections are rare, mostly occurring in Hong Kong, but clinically relevant, presenting as sepsis resulting from gastrointestinal disease [1, 2].

A 77-yr-old man was admitted to the hospital for febrile sensation and abdominal pain. Eight years previously, he underwent endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy for acute cholangitis with a common bile duct stone. He also had a history of hypertension, diabetes mellitus, dilated cardiomyopathy, and atrial fibrillation. Physical examination revealed tenderness over the right upper quadrant of the abdomen, and a diagnosis of acute cholecystitis was made. Laboratory parameters were as follows: leukocyte count,  $11.3 \times 10^9/L$  (neutrophils, 90.9%); Hb, 16.3 g/dL; platelet count,  $113 \times 10^9/L$ ; AST, 96 U/L; ALT, 52 U/L; alkaline phosphatase, 84 U/L;  $\gamma$ -glutamyl transpeptidase, 163 U/L; total bilirubin, 3.35 mg/dL; direct bilirubin, 1.68 mg/dL; and C-reactive protein, 8.6 mg/dL. Coagulation profiling revealed prolonged prothrombin time (PT, 23.0 sec) and activated partial thromboplastin time (aPTT, 54.1 sec) due to warfarin treatment. Abdominal CT showed

gallbladder stones, edematous thickening of the gallbladder wall, mild dilatation and pneumobilia in the left intrahepatic bile duct. The day after admission, ERCP and endoscopic retrograde biliary drainage was performed. Hemobilia originating from the gallbladder was detected, but an emergency operation could not be performed because of prolonged PT and aPTT.

Two blood cultures were obtained, and treatment with empirical intravenous cefodizime and metronidazole was initiated. On day 3 post-incubation, Gram-positive coccobacilli were isolated from the two anaerobic blood cultures. These organisms grew on sheep blood agar as non-hemolytic, white, pinpoint colonies after 48-72 hr of anaerobic incubation at 37°C (Fig. 1). The bacteria produced catalase. The isolate was not identified by phenotypic identification methods using the Vitek2 ANC card (bioMérieux, Marcy l'Etoile, France) or the API 20A system (bioMérieux). Two matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry instruments, a MALDI Biotyper (Bruker Daltonics Inc., Billerica, MA, USA) and a VITEK MS (bioMérieux), also could not identify the isolate. We therefore sequenced the 16S rRNA gene for identification at the species level [3]. The 16S rRNA sequences (1,358 bp) showed 100.0% similarity with the sequence of *C. hongkongensis* strains (GenBank accession no: LT223646.1, AB671763.1, NR\_115269.1).

**Received:** March 29, 2016

**Revision received:** June 30, 2016

**Accepted:** October 13, 2016

**Corresponding author:** Soo Hyun Kim

Department of Laboratory Medicine, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 61469, Korea


Tel: +82-61-379-7952, Fax: +82-61-379-7984

E-mail: alpinboy@chonnam.ac.kr

\*These authors equally contributed to this work.

© The Korean Society for Laboratory Medicine.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Fig. 1.** Macroscopic and microscopic appearance of the isolate. (A) They grew on sheep blood agar as non-hemolytic, white, pinpoint colonies after 48–72 hr of anaerobic incubation at 37°C. (B) Microscopic examination of the isolate showed gram-positive coccobacilli (Gram stain,  $\times 1,000$ ).

There were some differences in the biochemical test results of the isolate from that of genetically similar organisms: *Ruminococcus* species (GenBank accession no: AJ318864.1) that showed Gram-positive diplococci and catalase negativity and *Christensenella* species (GenBank accession no: LT223568.1) that showed Gram-negative bacilli. Thus, the pathogen was identified as *C. hongkongensis*.

Antimicrobial susceptibility testing was performed by E-test strips (bioMérieux) or disk diffusion method on Mueller–Hinton agar. Categorical interpretation according to CLSI breakpoints was used. The isolate was susceptible to vancomycin (minimum inhibitory concentration [MIC] 0.5–0.75  $\mu\text{g/mL}$ ) and metronidazole, but resistant to penicillin, cefotaxime (MIC  $> 32$   $\mu\text{g/mL}$ ), colistin, and gentamicin (MIC  $> 256$   $\mu\text{g/mL}$ ). After seven days of antibiotic treatment, the patient was discharged, and his operation was scheduled at the time of next admission. The patient underwent elective laparoscopic cholecystectomy and recovered without any complications.

*C. hongkongensis* has been recently described as a pathogen capable of causing bacteremia [1]. Only twelve cases of bloodstream infection with this organism have been reported to date (Table 1) [1, 4–7]. This patient recovered rapidly with antimicrobial therapy and surgery, but five of the 12 reported cases of *C. hongkongensis* bacteremia were fatal. Considering that *C. hongkongensis* bacteremia is often associated with complications and high mortality, especially in patients with advanced malig-

nancies [6], the importance of accurately identifying this microorganism should be highlighted in clinical microbiology laboratories. Our isolate was susceptible to vancomycin, similar to the isolates reported by Lau *et al* [6] in 2012. Six out of the seven (86%) patients who were treated with a combination of metronidazole and cefuroxime or cefodizime recovered, whereas four out of the 6 patients who had poor prognosis, i.e., death, were treated by other modalities. These results support the claim that metronidazole-based combination therapy with cefuroxime or cefodizime could be effective for treating *C. hongkongensis* bacteremia. Because phenotypic identification of *C. hongkongensis* is difficult and unreliable, the prevalence of infections caused by this organism is likely to be underestimated. Therefore, systemic gram-positive bacilli should not be ignored, and 16S rRNA gene sequencing is a unique technique for accurate species-level identification of *C. hongkongensis*.

### Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

### Acknowledgments

This work was supported by a research grant from the Research

**Table 1.** Summary of clinical findings and microbial characteristics of *Catabacter hongkongensis* causing bloodstream infections from the literature

No.	Age/ Sex	Location	Diagnosis/Underlying disease	Blood culture bottle (days to positive culture)	Treatment		Susceptibility (MIC, µg/mL) [S or R]					Reference
					Surgery	Medicine	Outcome	VAN	PEN	CEF	MET	
1	48/M	Hong Kong	Partial small bowel obstruction with secondary sepsis/CKD	AN (Day 3)	No	Cefuroxime & Metronidazole	Recovered	2 [S]	0.75 [S]	> 32 [R]	< 0.016 [S]	[1]
2	39/M	Hong Kong	Acute appendicitis with perforation	AN (Day 3)	Yes	Cefuroxime & Metronidazole	Recovered	2 [S]	0.5 [S]	> 32 [R]	< 0.016 [S]	[1]
3	74/M	Canada	Fever post exchange of biliary stent/plasmacytoma	NS	No	Ciprofloxacin	Recovered	2 [S]	4 [R]	> 32 [R]	< 0.016 [S]	[1]
4	66/F	Canada	Fever, sepsis syndrome/metastatic cancer of the lung	AN (Day 5)	No	Cefuroxime & Ciprofloxacin	Died	2 [S]	4 [R]	> 32 [R]	< 0.016 [S]	[1]
5	52/M	France	Intestinal perforation peritonitis, septic shock	AN (Day 3)	Yes	Amoxicillin-clavulanate & gentamicin	Died	< 0.016 [S]	2 [R]	> 32 [R]	< 0.016 [S]	[4]
6	47/M	New Zealand	Acute appendicitis with perforation/Perineal abscess	AN (Day 4)	Yes	Cefuroxime & Metronidazole, Amoxicillin-clavulanate	Recovered	-	4 [R]	- [S]	- [S]	[5]
7	91/F	Hong Kong	Sepsis, liver abscess/suspected GIT malignancy	AN (Day 3)	No	Ticarcillin-clavulanate & gentamicin	Died	0.75-1.0 [S]	< 0.016-0.032 [S]	> 32 [R]	< 0.016 [S]	[6]
8	21/M	Hong Kong	Acute gangrenous perforated appendicitis	AN (Day 3)	No	Cefuroxime & metronidazole	Recovered	0.75-1.0 [S]	< 0.016-0.032 [S]	> 32 [R]	< 0.016 [S]	[6]
9	81/F	Hong Kong	Sepsis/metastatic colon cancer	AN (Day 3)	No	Amoxicillin-clavulanate, piperacillin-tazobactam	Died	0.75-1.0 [S]	< 0.016-0.032 [S]	> 32 [R]	< 0.016 [S]	[6]
10	76/M	Hong Kong	Acute calculous cholecystitis	AN (Day 3)	No	Cefuroxime & metronidazole	Recovered	0.75-1.0 [S]	< 0.016-0.032 [S]	> 32 [R]	< 0.016 [S]	[6]
11	81/F	Hong Kong	Infected tumor/metastatic colon cancer	AN (Day 3)	No	Cefuroxime & metronidazole	Died	0.75-1.0 [S]	< 0.016-0.032 [S]	> 32 [R]	< 0.016 [S]	[6]
12	55/M	Italy	Septic shock	AN (Day 4)	No	Vancomycin & Meropenem	Recovered	0.75 [S]	-	-	≤ 0.16 [S]	[7]
13	77/M	South Korea	Acute cholecystitis	AN (Day 3)	Yes	Cefodizime & Metronidazole	Recovered	0.5-0.75 [S]	> 32 [R]	> 32 [R]	- [S]	This report

Abbreviations: AN, anaerobic bottle; MIC, minimum inhibitory concentration; CEF, cefotaxime; CKD, chronic kidney disease; GIT, gastrointestinal tract; MET, metronidazole; NS, not specified; PEN, penicillin; R, resistant for the agents on the basis of the CLSI clinical breakpoints for anaerobes; S, susceptible for the agents on the basis of the CLSI clinical breakpoints for anaerobes; VAN, vancomycin.

Institute of Medical Sciences, Chonnam National University (2010-CURIMS-DR007). We are grateful to Bong-Ju Kang, M.T. at the Laboratory of Clinical Microbiology of Chonnam National University Hospital for technical assistance.

## REFERENCES

1. Lau SK, McNabb A, Woo GK, Hoang L, Fung AM, Chung LM, et al. *Catabacter hongkongensis* gen. nov., sp. nov., isolated from blood cultures of patients from Hong Kong and Canada. *J Clin Microbiol* 2007;45:395-401.
2. Lau SK, Teng JL, Huang Y, Curreem SO, Tsui SK, Woo PC. Draft genome sequence of *Catabacter hongkongensis* type strain HKU16<sup>T</sup>, isolated from a patient with bacteremia and intestinal obstruction. *Genome Announc* 2015;3:e00531-15.
3. LiPuma JJ, Dulaney BJ, McMenamin JD, Whitby PW, Stull TL, Coenye T, et al. Development of rRNA-based PCR assays for identification of *Burkholderia cepacia* complex isolates recovered from cystic fibrosis patients. *J Clin Microbiol* 1999;37:3167-70.
4. Elsendoorn A, Robert R, Culos A, Roblot F, Burucoa C. *Catabacter hongkongensis* bacteremia with fatal septic shock. *Emerg Infect Dis* 2011;17:1330-1.
5. Smith K, Pandey SK, Ussher JE. Bacteraemia caused by *Catabacter hongkongensis*. *Anaerobe* 2012;18:366-8.
6. Lau SK, Fan RY, Lo HW, Ng RH, Wong SS, Li IW, et al. High mortality associated with *Catabacter hongkongensis* bacteremia. *J Clin Microbiol* 2012;50:2239-43.
7. Torri A, Delbianco F, Baccharini FD, Fusari M, Bertini S, Congestri F, et al. First report of sepsis due to *Catabacter hongkongensis* in an Italian patient. *New Microbes New Infect* 2015;9:54-5.